Cell and Gene Therapy
Refine Search
Biotechnology
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Biotechnology
Canada’s NanoVation Therapeutics, a privately-held platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, has announced a multi-year partnership with Danish drugmaker Novo Nordisk. 18 September 2024
Biotechnology
Gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy. 18 September 2024
Biotechnology
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Biotechnology
American mRNA-immunotherapy start-up Myeloid Therapeutics has launched a subsidiary, Aurora Biosynthetics, in Australia. 16 September 2024
Biotechnology
California, USA-based biotech BridgeBio Pharma saw its shares dip 4% to $29.60 yesterday on disappointing clinical results and the company’s decision to drop an early-stage candidate. 11 September 2024
Biotechnology
US gene therapies developer Affinia Therapeutics has appointed Rami Daoud as chief business and financial officer. 11 September 2024
Biotechnology
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
Biotechnology
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
Biotechnology
Arsenal Biosciences, a programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, has announced the close of an oversubscribed $325 million Series C financing round. 4 September 2024
Biotechnology
Chinese gene therapy specialist YolTech Therapeutics has entered into an exclusive licensing agreement with Salubris Pharmaceuticals (SHE: 002294). 3 September 2024
Biotechnology
US gene therapy biotech Tern Therapeutics has announced its launch and closing of a $15 million financing. 28 August 2024
Biotechnology
The UK’s National Health Service (NHS) got off to a good start with the introduction of cell and gene therapies but it must do more to get ready for the arrival of the advanced therapies of the future, according to a new report for the Association of the British Pharmaceutical Industry (ABPI). 19 August 2024
Biotechnology
US gene therapy company bluebird bio closed Wednesday’s trading 23% lower. 15 August 2024
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for gene therapy delandistrogene moxeparvovec, for the treatment of Duchenne muscular dystrophy (DMD). 15 August 2024
Biotechnology
CRISPR genome-editing biopharma company Caribou Biosciences has announced the appointment of Tina Albertson as chief medical officer (CMO). 13 August 2024
Biotechnology
Californian genetic medicines company 4D Molecular Therapeutics is free to continue with its Phase I/II INGLAXA study for the gene therapy 4D-310 in Fabry disease cardiomyopathy. 12 August 2024
Biotechnology
US biotech Gilead Sciences announced second quarter 2024 financials after markets closed on Thursday. 9 August 2024
Biotechnology
Vertex Pharmaceuticalsrevealed a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel), from today. 8 August 2024
Biotechnology
US cell and gene therapy company Precigen has announced a strategic reprioritization of the company's clinical portfolio and streamlining of resources. 8 August 2024
Biotechnology
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Biotechnology
Canada’s NanoVation Therapeutics, a privately-held platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, has announced a multi-year partnership with Danish drugmaker Novo Nordisk. 18 September 2024
Biotechnology
Gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy. 18 September 2024
Biotechnology
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Biotechnology
American mRNA-immunotherapy start-up Myeloid Therapeutics has launched a subsidiary, Aurora Biosynthetics, in Australia. 16 September 2024
Biotechnology
California, USA-based biotech BridgeBio Pharma saw its shares dip 4% to $29.60 yesterday on disappointing clinical results and the company’s decision to drop an early-stage candidate. 11 September 2024
Biotechnology
US gene therapies developer Affinia Therapeutics has appointed Rami Daoud as chief business and financial officer. 11 September 2024
Biotechnology
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
Biotechnology
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
Biotechnology
Arsenal Biosciences, a programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, has announced the close of an oversubscribed $325 million Series C financing round. 4 September 2024
Biotechnology
Chinese gene therapy specialist YolTech Therapeutics has entered into an exclusive licensing agreement with Salubris Pharmaceuticals (SHE: 002294). 3 September 2024
Biotechnology
US gene therapy biotech Tern Therapeutics has announced its launch and closing of a $15 million financing. 28 August 2024
Biotechnology
The UK’s National Health Service (NHS) got off to a good start with the introduction of cell and gene therapies but it must do more to get ready for the arrival of the advanced therapies of the future, according to a new report for the Association of the British Pharmaceutical Industry (ABPI). 19 August 2024
Biotechnology
US gene therapy company bluebird bio closed Wednesday’s trading 23% lower. 15 August 2024
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for gene therapy delandistrogene moxeparvovec, for the treatment of Duchenne muscular dystrophy (DMD). 15 August 2024
Biotechnology
CRISPR genome-editing biopharma company Caribou Biosciences has announced the appointment of Tina Albertson as chief medical officer (CMO). 13 August 2024
Biotechnology
Californian genetic medicines company 4D Molecular Therapeutics is free to continue with its Phase I/II INGLAXA study for the gene therapy 4D-310 in Fabry disease cardiomyopathy. 12 August 2024
Biotechnology
US biotech Gilead Sciences announced second quarter 2024 financials after markets closed on Thursday. 9 August 2024
Biotechnology
Vertex Pharmaceuticalsrevealed a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel), from today. 8 August 2024
Biotechnology
US cell and gene therapy company Precigen has announced a strategic reprioritization of the company's clinical portfolio and streamlining of resources. 8 August 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze